An interview with John Taylor, president and principal, compliance and regulatory affairs at FDA regulatory consulting firm Greenleaf Health

To allay fears about continuous manufacturing changes, utilize the valuable tools and resources that the FDA has created. Seeking the agency’s insight early will also give you a clearer path for success.

A conversation with Brian Stewart, senior director of emerging technologies at Thermo Fisher Scientific, and Rami Mitri, CEO/founder of One Hill Solutions

In a scenario where biomanufacturing processes move to a continuous flow, analyzers are producing data simultaneously, necessitating real-time processing and making the existence of cloud-based tools for data management crucial.

A conversation with Ohad Karnieli, CEO of Atvio Biotech, and Nina Bauer, commercial development lead for autologous cell therapy at Lonza

Innovators across the industry who want to see personalized medicine, such as autologous cell therapies, reach its full potential are focusing on developing technologies that can create realistic business models for these treatments.

By Dr. Barb Paldus, CEO, Finesse Solutions

Through the implementation of automation, data management, and analytical technologies, pharma has the opportunity to breathe new life into a number of areas of the biologics drug development process. Innovative research tools must be used to avoid spending time, money, and effort on products that have limited endpoint efficacy.